Souhaitez-vous accéder aux communiqués récents ?

Sitryx announces leadership transition Iain Kilty appointed Chief Executive Officer Neil Weir to assume role of President and remain on Board of Directors Oxford, UK – 2 July 2024 – Sitryx...

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...

Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometabolism-targeting pipeline into clinical development Ben Stephens brings seasoned operational and...

Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...

Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...

Oxford Science Enterprises (OSE) joins existing investors SV Health Investors, Lilly, Sofinnova Partners, Longwood Fund and GSKFollows original $30 million Series A raise, and brings total raised by...

Sitryx appoints Tanya E. Borsuk, Ph.D., as Chief Business Officer Oxford, UK – 10 November 2021 – Sitryx (“the Company”), a biopharmaceutical company focused on regulating cell metabolism to develop...

Sitryx licenses intellectual property rights for inhibitors of a new target in immunometabolism from Cancer Research UK in exclusive worldwide agreement Oxford, UK – 6 July 2021 – Sitryx (“the...

Sitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer Oxford, UK – 15 April 2021 – Sitryx (“the Company”), a biopharmaceutical company...

Sitryx appoints Pierre Legault as Chairman of its Board of Directors Oxford, UK – 24 March 2021 - Sitryx, a biopharmaceutical company focused on regulating cell metabolism to develop...